Drug Trial News

RSS

Meda announces positive results from three MP29-02 studies on allergic rhinitis

Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.

5 Mar 2012

SK Biopharmaceuticals' YKP3089 receives Korea Drug Development Fund

South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.

3 Mar 2012

Rigosertib drug shows promise against advanced pancreatic cancer

The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.

3 Mar 2012

Epicatechin-enriched cocoa shows promise against heart failure, Type 2 diabetes

A small clinical trial led by researchers at UC San Diego School of Medicine and VA San Diego Healthcare System (VASDHS) found that patients with advanced heart failure and type 2 diabetes showed improved mitochondrial structure after three months of treatment with epicatechin-enriched cocoa. Epicatechin is a flavonoid found in dark chocolate.

3 Mar 2012

Long-term data from Baxter's HyQ clinical study on PI

Baxter International Inc. today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies.

From Baxter International Inc. 3 Mar 2012

Preliminary results from Genentech's ACTEMRA monotherapy study on RA

Genentech, a member of the Roche Group, today announced that preliminary results from the ADACTA (ADalimumab ACTemrA) study showed that patients who received ACTEMRA (tocilizumab) as monotherapy achieved a significantly greater reduction in disease activity after 24 weeks than those given adalimumab monotherapy.

2 Mar 2012

BioInvent completes enrollment in BI-204 phase IIa study for atherosclerosis

BioInvent International AB and its collaborator Genentech, a member of the Roche Group, announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease.

2 Mar 2012

UCSD first to treat glioma with investigational viral vector

UC San Diego Moores Cancer Center researchers and surgeons are among the first in the nation to treat patients with recurrent brain cancer by directly injecting an investigational viral vector into their tumor. The treatment is being developed by a local San Diego Company, Tocagen Inc.

2 Mar 2012

Methylnaltrexone may restore bowel function in critically ill patients

Opioids are a mainstay of care in the critical care unit, but their use frequently causes constipation which can lead to adverse outcomes including delayed feeding and later discharge from the ICU. Researchers from London, UK, and Chicago, IL, have found that methylnaltrexone (MNTX), a peripheral opioid antagonist, may restore bowel function in critically ill patients.

2 Mar 2012

Positive results from AltheRx Solabegron Phase II study on overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the European Association of Urology Congress in Paris.

1 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

Ruxolitinib boosts QOL and survival for patients with myelofibrosis

A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine.

1 Mar 2012

NEJM publishes results from two Jakafi Phase III studies on MF

The New England Journal of Medicine (NEJM) today published results from two Phase III studies (COMFORT-I and COMFORT-II) of Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis.

1 Mar 2012

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

Study identifies how chemo drug combination kills pancreatic cancer cells

Cancer Research UK scientists have discovered how a combination of two chemotherapy drugs - already showing promise in clinical trials - destroys pancreatic cancer cells, according to research published in Cancer Discovery.

29 Feb 2012

DTMI, Bristol-Myers Squibb partner to broaden interactions

Bristol-Myers Squibb Company and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to broaden interactions between the two organizations.

28 Feb 2012

FDA accepts Tau Therapeutics' mibefradil IND for treatment of cancer

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).

28 Feb 2012

TAK-875 - an emerging therapy for Type 2 diabetes

In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego.

28 Feb 2012

DBV receives FDA Fast Track Designation for Viaskin Peanut clinical development program

DBV Technologies announced today that it has received "Fast Track Designation" for the Clinical Development Program of its Viaskin Peanut, a product designed for the treatment by Epicutaneous Immunotherapy (EPIT) of patients with peanut allergy.

28 Feb 2012

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.

28 Feb 2012